IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v89y2009i2p184-192.html

Public health policy decisions on medical innovations: What role can early economic evaluation play?

Author

Listed:
  • Hartz, Susanne
  • John, Jürgen

Abstract

Objectives Our contribution aims to explore the different ways in which early economic data can inform public health policy decisions on new medical technologies.Methods A literature research was conducted to detect methodological contributions covering the health policy perspective.Results Early economic data on new technologies can support public health policy decisions in several ways. Embedded in horizon scanning and HTA activities, it adds to monitoring and assessment of innovations. It can play a role in the control of technology diffusion by informing coverage and reimbursement decisions as well as the direct public promotion of healthcare technologies, leading to increased efficiency. Major problems include the uncertainty related to economic data at early stages as well as the timing of the evaluation of an innovation.Conclusions Decision-makers can benefit from the information supplied by early economic data, but the actual use in practice is difficult to determine. Further empirical evidence should be gathered, while the use could be promoted by further standardization.

Suggested Citation

  • Hartz, Susanne & John, Jürgen, 2009. "Public health policy decisions on medical innovations: What role can early economic evaluation play?," Health Policy, Elsevier, vol. 89(2), pages 184-192, February.
    • Handle: RePEc:eee:hepoli:v:89:y:2009:i:2:p:184-192
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(08)00128-0
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to look for a different version below or

    for a different version of it.

    Other versions of this item:

    References listed on IDEAS

    as
    1. Drummond, Michael F. & Sculpher, Mark J. & Torrance, George W. & O'Brien, Bernie J. & Stoddart, Greg L., 2005. "Methods for the Economic Evaluation of Health Care Programmes," OUP Catalogue, Oxford University Press, edition 3, number 9780198529453.
    2. Banta, David, 2003. "The development of health technology assessment," Health Policy, Elsevier, vol. 63(2), pages 121-132, February.
    3. McDaid, David & Cookson, Richard AU -, 2003. "Evaluating health care interventions in the European Union," Health Policy, Elsevier, vol. 63(2), pages 133-139, February.
    4. Banta, H. David & Vondeling, Hindrik, 1994. "Strategies for successful evaluation and policy-making toward health care technology on the move: The case of medical lasers," Social Science & Medicine, Elsevier, vol. 38(12), pages 1663-1674, June.
    5. Maynard, Alan & McDaid, David, 2003. "Evaluating health interventions: exploiting the potential," Health Policy, Elsevier, vol. 63(2), pages 215-226, February.
    6. Ernst R. Berndt & Rachel Glennerster & Michael R. Kremer & Jean Lee & Ruth Levine & Georg Weizsäcker & Heidi Williams, 2007. "Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness," Health Economics, John Wiley & Sons, Ltd., vol. 16(5), pages 491-511, May.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Rozmarinová Jana & Říhová Barbora, 2021. "Health Technology Assessment of the Medical Devices: A Case Study from the Czech Republic," NISPAcee Journal of Public Administration and Policy, Sciendo, vol. 14(2), pages 253-272, December.
    2. Vogler, Sabine & Zimmermann, Nina & de Joncheere, Kees, 2016. "Policy interventions related to medicines: Survey of measures taken in European countries during 2010–2015," Health Policy, Elsevier, vol. 120(12), pages 1363-1377.
    3. Mariola Zalewska, 2011. "Effectiveness of health care in the OECD and EU countries with the innovation factor taken into account (Efektywnosc w ochronie zdrowia w krajach OECD i UE z uwzglednieniem czynnika innowacyjnosci)," Problemy Zarzadzania, University of Warsaw, Faculty of Management, vol. 9(33), pages 42-61.
    4. Markiewicz, Katarzyna & van Til, Janine A. & Steuten, Lotte M.G. & IJzerman, Maarten J., 2016. "Commercial viability of medical devices using Headroom and return on investment calculation," Technological Forecasting and Social Change, Elsevier, vol. 112(C), pages 338-346.
    5. W. Dominika Wranik & Liesl Gambold & Natasha Hanson & Adrian Levy, 2017. "The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?," International Journal of Health Planning and Management, Wiley Blackwell, vol. 32(2), pages 232-260, April.
    6. Gabriele Palozzi & Sandro Brunelli & Camilla Falivena, 2018. "Higher Sustainability and Lower Opportunistic Behaviour in Healthcare: A New Framework for Performing Hospital-Based Health Technology Assessment," Sustainability, MDPI, vol. 10(10), pages 1-19, October.
    7. Maarten Ijzerman & Lotte Steuten, 2011. "Early assessment of medical technologies to inform product development and market access," Applied Health Economics and Health Policy, Springer, vol. 9(5), pages 331-347, September.
    8. Shavit, Oren, 2009. "Utilization of health technologies--Do not look where there is a light; shine your light where there is a need to look!: Relating national health goals with resource allocation decision-making; illust," Health Policy, Elsevier, vol. 92(2-3), pages 268-275, October.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Ciani, Oriana & Tarricone, Rosanna & Torbica, Aleksandra, 2012. "Diffusion and use of health technology assessment in policy making: What lessons for decentralised healthcare systems?," Health Policy, Elsevier, vol. 108(2), pages 194-202.
    2. Rogowski, Wolf, 2007. "Current impact of gene technology on healthcare: A map of economic assessments," Health Policy, Elsevier, vol. 80(2), pages 340-357, February.
    3. Laurent Molinier & Hélène Bocquet & Vanina Bongard & Bernard Fraysse, 2009. "The economics of cochlear implant management in France: a multicentre analysis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(3), pages 347-355, July.
    4. Dyfrig Hughes & Joanna Charles & Dalia Dawoud & Rhiannon Tudor Edwards & Emily Holmes & Carys Jones & Paul Parham & Catrin Plumpton & Colin Ridyard & Huw Lloyd-Williams & Eifiona Wood & Seow Tien Yeo, 2016. "Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches," PharmacoEconomics, Springer, vol. 34(5), pages 447-461, May.
    5. Paal Joranger & Arild Nesbakken & Halfdan Sorbye & Geir Hoff & Arne Oshaug & Eline Aas, 2020. "Survival and costs of colorectal cancer treatment and effects of changing treatment strategies: a model approach," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 321-334, April.
    6. Mara Airoldi & Alec Morton & Jenifer A. E. Smith & Gwyn Bevan, 2014. "STAR—People-Powered Prioritization," Medical Decision Making, , vol. 34(8), pages 965-975, November.
    7. Refoios Camejo, Rodrigo & McGrath, Clare & Herings, Ron, 2011. "A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness," Health Policy, Elsevier, vol. 100(1), pages 18-24, April.
    8. Saha, Sanjib & Gerdtham, Ulf-G. & Toresson, Håkan & Minthon, Lennart & Jarl, Johan, 2018. "Economic Evaluation of Interventions for Screening of Dementia," Working Papers 2018:20, Lund University, Department of Economics.
    9. Mark Oppe & Daniela Ortín-Sulbarán & Carlos Vila Silván & Anabel Estévez-Carrillo & Juan M. Ramos-Goñi, 2021. "Cost-effectiveness of adding Sativex® spray to spasticity care in Belgium: using bootstrapping instead of Monte Carlo simulation for probabilistic sensitivity analyses," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(5), pages 711-721, July.
    10. Laurence M. Djatche & Stefan Varga & Robert D. Lieberthal, 2018. "Cost-Effectiveness of Aspirin Adherence for Secondary Prevention of Cardiovascular Events," PharmacoEconomics - Open, Springer, vol. 2(4), pages 371-380, December.
    11. Ties Hoomans & Johan Severens & Nicole Roer & Gepke Delwel, 2012. "Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands," PharmacoEconomics, Springer, vol. 30(3), pages 219-227, March.
    12. Nadja Chernyak & Heribert Sattel & Marsel Scheer & Christina Baechle & Johannes Kruse & Peter Henningsen & Andrea Icks, 2014. "Economic Evaluation of Brief Psychodynamic Interpersonal Therapy in Patients with Multisomatoform Disorder," PLOS ONE, Public Library of Science, vol. 9(1), pages 1-4, January.
    13. Catherine Pitt & Catherine Goodman & Kara Hanson, 2016. "Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature," Health Economics, John Wiley & Sons, Ltd., vol. 25(S1), pages 9-28, February.
    14. Khan, Mohammed Tajuddin & Kishore, Avinash & Joshi, Pramod K., 2016. "Gender dimensions on farmers’ preferences for direct-seeded rice with drum seeder in India," IFPRI discussion papers 1550, International Food Policy Research Institute (IFPRI).
    15. Daphne C. Voormolen & Judith A. M. Bom & Esther W. de Bekker-Grob & Werner B. F. Brouwer & Job van Exel, 2024. "Development and Content Validation of the 10-item Well-being Instrument (WiX) for use in Economic Evaluation Studies," Applied Research in Quality of Life, Springer;International Society for Quality-of-Life Studies, vol. 19(2), pages 381-413, April.
    16. Noémi Kreif & Richard Grieve & M. Zia Sadique, 2013. "Statistical Methods For Cost‐Effectiveness Analyses That Use Observational Data: A Critical Appraisal Tool And Review Of Current Practice," Health Economics, John Wiley & Sons, Ltd., vol. 22(4), pages 486-500, April.
    17. Ângela J. Ben & Jeruza L. Neyeloff & Camila F. Souza & Ana Paula O. Rosses & Aline L. Araujo & Adriana Szortika & Franciele Locatelli & Gabriela Carvalho & Cristina R. Neumann, 2020. "Cost-utility Analysis of Opportunistic and Systematic Diabetic Retinopathy Screening Strategies from the Perspective of the Brazilian Public Healthcare System," Applied Health Economics and Health Policy, Springer, vol. 18(1), pages 57-68, February.
    18. Elbe, Stefan & Roemer-Mahler, Anne & Long, Christopher, 2015. "Medical countermeasures for national security: A new government role in the pharmaceuticalization of society," Social Science & Medicine, Elsevier, vol. 131(C), pages 263-271.
    19. Barbara Graaff & Lei Si & Amanda L. Neil & Kwang Chien Yee & Kristy Sanderson & Lyle C. Gurrin & Andrew J. Palmer, 2017. "Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model," PharmacoEconomics - Open, Springer, vol. 1(1), pages 37-51, March.
    20. Christopher Fitzpatrick & Katherine Floyd, 2012. "A Systematic Review of the Cost and Cost Effectiveness of Treatment for Multidrug-Resistant Tuberculosis," PharmacoEconomics, Springer, vol. 30(1), pages 63-80, January.

    More about this item

    Keywords

    ;

    JEL classification:

    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:89:y:2009:i:2:p:184-192. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.